Literature DB >> 18926622

Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection.

Axel Heidenreich1, David Pfister, Ralf Witthuhn, David Thüer, Peter Albers.   

Abstract

BACKGROUND: The anatomical extent of postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) has been discussed controversially for many years.
OBJECTIVE: To evaluate the necessity of PC-RPLND with modified or radical template resection in patients with advanced nonseminomatous germ-cell tumors (NSGCT) and residual masses following systemic chemotherapy. DESIGN, SETTING, AND PARTICIPANTS: The charts of 152 consecutive patients who were treated at two tertiary referral centers were retrospectively reviewed. INTERVENTION: All patients underwent PC-RPLND, with 54 and 98 patients undergoing a radical template resection and 98 patients undergoing a modified template resection. Modified template resection was performed if the location of the residual mass corresponded to the primary landing zone of testis cancer and the residual mass measured < or = 5 cm in diameter. In all other cases a full bilateral PC-RPLND was chosen. MEASUREMENTS: The following data were analyzed: location of the residual mass, extent of surgery, length of surgery, treatment-associated complications, nerve-sparing approach, adjunctive surgical procedures, postoperative morbidity, duration of hospital stay, early and late complications, relapse rates, cancer-specific survival rates, and overall survival rates. RESULTS AND LIMITATIONS: Overall, 84 patients (55.2%) had necrosis/fibrosis, 45 (29.6%) had mature teratoma, and 23 (15.1%) had vital cancer in the surgical specimens. Antegrade ejaculation was preserved in 85% and 25% of patients undergoing modified and bilateral PC-RPLND (p=0.02), respectively. Eight recurrences (5.2%) were observed after a mean follow-up of 39 mo (range 6-105 mo): one patient had an in-field relapse following modified PC-RPLND, and seven patients had recurrences outside the boundaries of full bilateral PC-RPLNDs. The 2-yr disease-free survival rates were 78.6% and 92.8% for bilateral and modified PC-RPLND, respectively. The limitations of this study were a short follow-up, a limited number of patients, and the retrospective nature of the study.
CONCLUSIONS: Full bilateral PC-RPLND is the standard approach to extensive residual masses. In well-defined masses a modified template PC-RPLND does not interfere with oncologic outcome but decreases treatment-associated morbidity.

Entities:  

Mesh:

Year:  2008        PMID: 18926622     DOI: 10.1016/j.eururo.2008.09.027

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  49 in total

Review 1.  [What is new in 2011 regarding testicular cancer].

Authors:  S Krege
Journal:  Urologe A       Date:  2011-09       Impact factor: 0.639

2.  [Comments on retroperitoneal lymphadenectomy - laparoscopic versus robotic].

Authors:  A Heidenreich
Journal:  Urologe A       Date:  2012-05       Impact factor: 0.639

3.  External validation of the Heidenreich criteria for patient selection for unilateral or bilateral retroperitoneal lymph node dissection for post-chemotherapy residual masses of testicular cancer.

Authors:  Cédric Vallier; Pierre-Henri Savoie; Jean-Robert Delpero; Franck Bladou; Gwenaëlle Gravis; Naji Salem; Dominique Rossi; Jochen Walz
Journal:  World J Urol       Date:  2014-01-20       Impact factor: 4.226

Review 4.  [Diagnosis, treatment and follow-up of testicular cancer].

Authors:  Susanne Krege
Journal:  Urologe A       Date:  2017-12       Impact factor: 0.639

5.  [Post-chemotherapy laparoscopic retroperitoneal lymph node dissection in low volume residual germ cell cancer: a technique to reduce morbidity].

Authors:  S Aufderklamm; T Todenhöfer; J Hennenlotter; G Gakis; J Mischinger; J Mundhenk; M Germann; A Stenzl; C Schwentner
Journal:  Urologe A       Date:  2013-08       Impact factor: 0.639

6.  Management of residual mass in nonseminomatous germ cell tumors following chemotherapy.

Authors:  Siamak Daneshmand; Hooman Djaladat; Craig Nichols
Journal:  Ther Adv Urol       Date:  2011-08

7.  [Complex residual tumors after chemotherapy of nonseminomatous germ cell tumors. Laparoscopic management - limits and chances].

Authors:  S Aufderklamm; T Todenhöfer; J Hennenlotter; J Mischinger; A Sim; J Böttge; S Rausch; S Bier; O Halalsheh; A Stenzl; G Gakis; C Schwentner
Journal:  Urologe A       Date:  2015-07       Impact factor: 0.639

Review 8.  [When is surgical resection of metastases in testicular germ cell tumors indicated and is there a scientific basis?]

Authors:  A Heidenreich; P Paffenholz; F Haidl; D Pfister
Journal:  Urologe A       Date:  2017-05       Impact factor: 0.639

9.  Post-chemotherapy robotic retroperitoneal lymph node dissection (RRPLND) in testicular cancer.

Authors:  Mohamed H Kamel; C Mark Jackson; John T Moore; Samy M Heshmat; Nabil K Bissada
Journal:  J Robot Surg       Date:  2012-03-09

10.  Management of post-chemotherapy residual mass in patients with metastatic nonseminomatous germ cell tumors of the testis.

Authors:  John P Fitzgerald; Barbara Ercole; Dipen J Parekh
Journal:  Indian J Urol       Date:  2010 Jan-Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.